Search results for "Liver cirrhosis."

showing 10 items of 598 documents

Altered postural control and stability in cirrhotic patients with minimal hepatic encephalopathy correlate with cognitive deficits

2017

Background & Aims: Cognitive dysfunction in cirrhotic patients with minimal hepatic encephalopathy (MHE) is associated with falls. Alterations in postural control and stability could contribute to increase falls risk in these patients. We aimed to assess whether postural control and direction-specific limits of stability are altered in cirrhotic patients with MHE compared to patients without MHE and controls. We also assessed if alterations in postural control correlate with neurological impairment and/or blood biomarkers. Methods: Posturography analysis, attention Stroop test and bimanual and visuo-motor coordination tests were performed in 18 controls, 19 patients with cirrhosis without M…

Liver CirrhosisMaleCirrhosisPsychometricslimits of stabilityminimal hepatic encephalopathypostural control03 medical and health sciencesCognition0302 clinical medicineAmmoniaPredictive Value of TestsRisk FactorsfallsOdds RatiomedicineHumansAttentionPhysical ExaminationPostural BalanceHepatic encephalopathyBalance (ability)Chi-Square DistributionHepatologyImpaired Balancebusiness.industryInterleukinsPosturographyCognitionMiddle Agedmedicine.diseaseMotor coordinationLogistic ModelsCase-Control StudiesHepatic EncephalopathyAnesthesiaMultivariate AnalysisSensation DisordersStroop TestAccidental FallsFemale030211 gastroenterology & hepatologyCognition Disordersbusinesshuman activitiesPsychomotor Performance030217 neurology & neurosurgeryStroop effect
researchProduct

Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients

2014

Summary Background Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice. Aim To investigate whether clinical complications of cirrhosis may define different prognostic disease stages. Methods Analysis of the database from a prospective inception cohort of 494 patients. Decompensation was defined by ascites, bleeding, jaundice or encephalopathy. Explored potential prognostic stages: 1, compensated cirrhosis without oesophago-gastric varices; 2, compensated cirrhosis with varices; 3, bleeding without other complications; 4, first nonbleeding decompensation; 5, any second decompensating event.…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaDatabases Factualmedicine.medical_treatmentLiver transplantationGastroenterologyCohort StudiesModel for End-Stage Liver DiseaseAscitesEsophageal and Gastric VariceMedicinePharmacology (medical)Prospective StudiesProspective cohort studyLiver NeoplasmsGastroenterologyAscitesJaundiceMiddle AgedPrognosisLiver NeoplasmAsciteDisease ProgressionFemalemedicine.symptomHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularPrognosiLiver CirrhosiJaundiceEsophageal and Gastric VaricesRisk AssessmentFollow-Up StudieInternal medicineHumansDecompensationAgedHepatologybusiness.industrymedicine.diseaseLiver TransplantationProspective StudieCohort StudiebusinessVaricesFollow-Up Studies
researchProduct

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

2018

Background & Aims: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus–associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. Methods: We collected data from a large prospective study of 2,249 consecutive patients (mean age = 65.4 years, 56.9% male) with hepatitis C virus–associated cirrhosis (90.5% with Child-Pugh class A and 9.5% with Child-Pugh class B) treated with DAAs from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. HCC occurren…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaSustained Virologic ResponseHepacivirusGastroenterology0302 clinical medicineRESIST-HCVRisk FactorsHepatocellular Carcinoma (HCC)MedicineLiver Cancer RiskProspective StudiesProspective cohort studySettore MED/12 - GastroenterologiaIncidence (epidemiology)IncidenceLiver NeoplasmsGastroenterologyHepatitis CMiddle AgedCirrhosis; Direct Antiviral Agents (DAAs); Hepatocellular Carcinoma (HCC); RESIST-HCV; Sustained Virological Response (SVR); hepatitis C Virus (HCV); liver cancer risk; reduction; sofosbuvirCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomahepatitis C Virus (HCV)030211 gastroenterology & hepatologyFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularDirect Antiviral Agents (DAAs)Liver CirrhosiRESIST-HCV Liver Cancer Risk Reduction SofosbuvirAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicineHumansIn patientSustained Virological Response (SVR)AgedReductionAntiviral AgentHepaciviruHepatologybusiness.industryProportional hazards modelRisk FactorHepatitis C Chronicmedicine.diseasedigestive system diseasesProspective StudieChild-Pugh Class BSofosbuvirbusinessFollow-Up Studies
researchProduct

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.

2016

Clearance of hepatitis C virus (HCV) via antiviral treatment changes the course of liver disease. We evaluated the benefit of sustained virologic response (SVR) in patients with HCV and cirrhosis without (stage 1) and with (stage 2) esophageal varices (EV).We performed a prospective cohort study of 444 patients with HCV and compensated cirrhosis (218 with stage 1 and 226 with stage 2 disease) treated with peg-interferon and ribavirin from June 2001 through December 2009 at the University of Palermo, Italy and followed for a median of 7.6 years (range, 1-12.6 years). We used Cox regression analysis to identify variables associated with appearance or progression of EVs, development of hepatoc…

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepacivirusEsophaguGastroenterologyPolyethylene GlycolsLiver diseasechemistry.chemical_compound0302 clinical medicineEsophageal varicesProspective StudiesProspective cohort studyHazard ratioGastroenterologyvirus diseasesMiddle AgedPortal PressureHepatitis CRecombinant ProteinsIntention to Treat AnalysisItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemalemedicine.medical_specialtyInterferon alpha-2Lower riskEsophageal and Gastric VaricesAntiviral Agents03 medical and health sciencesInternal medicineHypertension PortalRibavirinmedicineHumansAgedProportional Hazards ModelsHepatologybusiness.industryRibavirinBleedingInterferon-alphaLong-Term Outcomemedicine.diseasedigestive system diseaseschemistrybusinessFollow-Up StudiesGastroenterology
researchProduct

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

2018

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous …

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepatocellular carcinomaDirect antiviral agentsDIRECT ACTING ANTIVIRALSGastroenterologyCohort Studies0302 clinical medicineRisk FactorsChronicIncidence (epidemiology)Liver NeoplasmsGastroenterologyMiddle AgedHepatitis CTumor recurrenceCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinoma; Aged; Antiviral Agents; Carcinoma Hepatocellular; Cohort Studies; Disease Progression; Female; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Risk Factors; alpha-Fetoproteins; Sustained Virologic ResponseItalyLocalCirrhosis030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease ProgressionPortal hypertension030211 gastroenterology & hepatologyFemalealpha-FetoproteinsCohort studymedicine.medical_specialtyCarcinoma HepatocellularEarly RecurrenceAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedCirrhosiHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseasedigestive system diseasesNeoplasm RecurrenceDirect antiviral agentNeoplasm Recurrence LocalCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinomabusiness
researchProduct

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.

2011

Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difficult to predict. We evaluated collagen proportionate area (CPA), a quantitative histological index, at 1 year with respect to the first episode of clinical decompensation. Patients with biopsies at 1 year after liver transplantation were evaluated by Ishak stage/grade, and biopsy samples stained with Sirius red for digital image analysis were evaluated for CPA. Cox regression was used to evaluate variables associated with first appearance of clinical decompensation. Receiver operating characteristic (ROC) curves were also used. A total of 135 patients with median follow-up of 76 months were evaluated. At 1…

Liver CirrhosisMaleCirrhosisTime FactorsPortal venous pressuremedicine.medical_treatmentBiopsyKaplan-Meier EstimateLiver transplantationmedicine.disease_causeGastroenterologyRecurrenceRisk FactorsLondonChildFirst episodemedicine.diagnostic_testMiddle AgedHepatitis CLiverFemaleCollagenAdultmedicine.medical_specialtyAdolescentHepatitis C virusHepatic VeinsRisk AssessmentSensitivity and SpecificityEnd Stage Liver DiseaseYoung AdultPredictive Value of TestsInternal medicineBiopsyImage Interpretation Computer-AssistedmedicineHumansDecompensationAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologybusiness.industrymedicine.diseaseSurgeryLiver TransplantationTransplantationROC CurveSurgerybusinessVenous PressureLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.

2005

Background & Aims: Transcatheter arterial chemoembolization (TACE) currently is used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its efficacy still is debated. Our aim was to assess the impact of TACE on patient survival and to identify prognostic factors for survival. Methods: Fifty-six cirrhotic patients with unresectable HCC undergoing at least :1 course of TACE were matched 1:1. for sex, age (in 5-year periods), parameters of Child-Pugh score, Okuda stage, and tumor type with a control group who had received only supportive care. Results: The 2 groups were comparable for cause of cirrhosis, alpha-fetoprotein serum levels, and Cancer of th…

Liver CirrhosisMaleCirrhosisTime FactorsPrognostic systemGastroenterologyOily chemoembolizationHepatic ArteryCause of DeathAscitesValidationMedicineStage (cooking)CIRRHOSISUnivariate analysisAntibiotics AntineoplasticLiver NeoplasmsGastroenterologyLiver-TransplantationMiddle AgedHEPATOCELLULAR CARCINOMA; CIRRHOSIS; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; SURVIVAL; SIDE EFFECTSPrognosisTreatment OutcomeItalyRandomized controlled trialHepatocellular carcinomaSURVIVALFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularMultivariate-analysiTransarterial chemoembolizationInternal medicineSIDE EFFECTSCarcinomaHumansHEPATOCELLULAR CARCINOMAChemoembolization TherapeuticTranscatheter arterial chemoembolizationSurvival analysisAgedEpirubicinNeoplasm StagingCirrhosiHepatologybusiness.industrymedicine.diseaseSurvival AnalysisSurgeryLipiodol chemoembolizationTRANSCATHETER ARTERIAL CHEMOEMBOLIZATIONCase-Control StudiesMultivariate AnalysisbusinessFollow-Up StudiesClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological re…

2017

Background Few studies examined the outcome of patients with hepatitis C virus (HCV)-related cirrhosis who developed hepatocellular carcinoma (HCC). The relative weight as determinant of death for cancer vs end-stage liver disease (ESLD) and the benefit of HCV eradication remain undefined. This multicentre, retrospective analysis evaluates overall survival (OS), rate of decompensation and tumour recurrence in compensated HCC patients treated with interferon (IFN) according to HCV status since HCC diagnosis. Methods Two groups of patients with HCV-related cirrhosis and HCC were followed since HCC diagnosis: (i) compensated cirrhotics with prior sustained virological response (SVR) on IFN-bas…

Liver CirrhosisMaleCirrhosisTime FactorsSustained Virologic ResponseHepacivirusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyLiver disease0302 clinical medicineRisk Factorshepatitis C viruLiver Neoplasmsvirus diseasesHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseLiver cancermedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virussurvivalAntiviral Agents03 medical and health sciencesInternal medicineRibavirinmedicinehepatitis C virus; hepatocellular carcinoma; interferon; survival; sustained virological response; HepatologyHumansDecompensationPropensity ScoreAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryHepatologymedicine.diseasedigestive system diseasesMultivariate AnalysisInterferonsNeoplasm Recurrence LocalbusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct

Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic …

2020

Abstract Background and aim Increased intestinal permeability plays a key role in the pathogenesis of fat deposition in the liver. The aim of our study was to assess whether a single nucleotide polymorphism of protein tyrosine phosphatase non-receptor type 2 (PTPN2) (rs2542151 T→G), involved in intestinal permeability, may be associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods and results We recruited a prospective cohort of NAFLD subjects and matched controls. Clinical data, PTPN2 genotype and laboratory data were collected for each patient. Results were stratified according to liver histology and diabetes. We enrolled 566 cases and 377 co…

Liver CirrhosisMaleEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologySeverity of Illness IndexGastroenterologyLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasePrevalenceProspective StudiesProtein Tyrosine Phosphatase Non-Receptor Type 2Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedPhenotypeItalyLiver biopsyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIA030209 endocrinology & metabolismIntestinal permeabilityPolymorphism Single NucleotideRisk AssessmentPermeability03 medical and health sciencesInternal medicineDiabetes mellitusmedicineGenetic susceptibilityHumansNonalcoholic fatty liver diseaseGenetic Predisposition to DiseaseGenetic Association Studiesbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 2Intestinal AbsorptionCase-Control StudiesSteatosisSteatohepatitisbusiness
researchProduct